PHARMABIZ.com
india's most comprehensive pharma portal

Venus bags another product patent for Potentox from South Africa

Thursday, November 12, 2009 15:15 IST
Our Bureau, Mumbai

Venus Remedies, a research based pharma company, has received fifth product patent in the current year. CIPRO (Companies and Intellectual Property Registration Office) has granted third product patent in South Africa after Sulbactomax and Tobracef. This is also the third patent of Potentox within five months of its first grant in South Korea.

Potentox is a unique super specialty product with combination of a cephalosporin with aminoglycoside indicated for the treatment of hospital acquired pneumonia, community acquired pneumonia and Febrile Neutropenia.

WHO data suggest that there are 4.50 million cases of pneumonia, are a leading cause of death and years of life last in South Africa. It is fifth leading cause of death in females and seventh major cause of mortality in males. In Sub-Saharan Africa among HIV-infected patients presenting with a lower respiratory tract infection have confirmed that community-acquired pneumonia is the second cause of death with incidence of pneumonia due to S. pneumonae rising to 34.5 per cent. Venus Medicine Research center developed Potentox after an extensive research on current treatment trends for pneumonia, causes of their failures, reasons for drug resistance in order to bring out an innovative solution with can not only reduce the treatment time for pneumonia from 21-30 days to 7-10 days but also reduced drug and disease induced toxicities. This makes Potentox ideal for the treatment of HAP and CAP as number of adverse drug reactions are drastically reduced making the drug safe even for paediatric use.

In South Africa currently 8 per cent gross domestic product (GDP) is spent on health and more than half of the is amount is channelled into medical insurance schemes that serve the indicates that there is huge gap in demand and supply keeping in view the mortality in African continent. Venus expects to fetch good share in its kitty by out licensing and selling Potentox in African continent.

The product was launched in Indian market two years back after completion of all preclinical and multicentric phase-III clinical trials on more than 300 patients after DCGI approval. Later after the launch post marketing phase-IV studies were also conducted to re-establish the safety of drug. Company is in the process of out licensing and further registration of Portentox in South African market.